One possible explanation for the heterogeneity observed in the profiles of DNMT3A is that although our oncopediatric population was homogeneous in terms of hematological neoplasms and treatment with MTX®, it was not homogeneous in terms of the type of neoplasm or chemotherapy regimen, which may have included drugs other than MTX®. This evidence concerns the gene DNMT3A and hematopoietic and lymphoid system neoplasm.